190 related articles for article (PubMed ID: 21479995)
1. The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice.
Gladue RP; Paradis T; Cole SH; Donovan C; Nelson R; Alpert R; Gardner J; Natoli E; Elliott E; Shepard R; Bedian V
Cancer Immunol Immunother; 2011 Jul; 60(7):1009-17. PubMed ID: 21479995
[TBL] [Abstract][Full Text] [Related]
2. Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation.
Carpenter EL; Mick R; Rüter J; Vonderheide RH
J Transl Med; 2009 Nov; 7():93. PubMed ID: 19906293
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
4. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
[TBL] [Abstract][Full Text] [Related]
5. Distinctive maturation of in vitro versus in vivo anti-CD40 mAb-matured dendritic cells in mice.
Frleta D; Lin JT; Quezada SA; Wade TK; Barth RJ; Noelle RJ; Wade WF
J Immunother; 2003; 26(1):72-84. PubMed ID: 12514431
[TBL] [Abstract][Full Text] [Related]
6. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response.
Osada T; Nagawa H; Takahashi T; Tsuno NH; Kitayama J; Shibata Y
J Immunother; 2002; 25(2):176-84. PubMed ID: 12074047
[TBL] [Abstract][Full Text] [Related]
8. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.
Hunter TB; Alsarraj M; Gladue RP; Bedian V; Antonia SJ
Scand J Immunol; 2007 May; 65(5):479-86. PubMed ID: 17444959
[TBL] [Abstract][Full Text] [Related]
9. Anti-CD40 Antibodies Fused to CD40 Ligand Have Superagonist Properties.
Ceglia V; Zurawski S; Montes M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
J Immunol; 2021 Oct; 207(8):2060-2076. PubMed ID: 34551965
[TBL] [Abstract][Full Text] [Related]
10. Development of CDX-1140, an agonist CD40 antibody for cancer immunotherapy.
Vitale LA; Thomas LJ; He LZ; O'Neill T; Widger J; Crocker A; Sundarapandiyan K; Storey JR; Forsberg EM; Weidlick J; Baronas AR; Gergel LE; Boyer JM; Sisson C; Goldstein J; Marsh HC; Keler T
Cancer Immunol Immunother; 2019 Feb; 68(2):233-245. PubMed ID: 30382327
[TBL] [Abstract][Full Text] [Related]
11. Antigen presentation and immune regulatory capacity of immature and mature-enriched antigen presenting (dendritic) cells derived from human bone marrow.
Jin Y; Fuller L; Ciancio G; Burke GW; Tzakis AG; Ricordi C; Miller J; Esquenzai V
Hum Immunol; 2004 Feb; 65(2):93-103. PubMed ID: 14969764
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous targeting of CD3 on T cells and CD40 on B or dendritic cells augments the antitumor reactivity of tumor-primed lymph node cells.
Li Q; Grover AC; Donald EJ; Carr A; Yu J; Whitfield J; Nelson M; Takeshita N; Chang AE
J Immunol; 2005 Aug; 175(3):1424-32. PubMed ID: 16034078
[TBL] [Abstract][Full Text] [Related]
13. Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2.
Fayette J; Dubois B; Vandenabeele S; Bridon JM; Vanbervliet B; Durand I; Banchereau J; Caux C; Brière F
J Exp Med; 1997 Jun; 185(11):1909-18. PubMed ID: 9166420
[TBL] [Abstract][Full Text] [Related]
14. Enhanced CD40 and ICOSL expression on dendritic cells surface improve anti-tumor immune responses; effectiveness of mRNA/chitosan nanoparticles.
Daneshmandi S; Pourfathollah AA; Forouzandeh-Moghaddam M
Immunopharmacol Immunotoxicol; 2018 Oct; 40(5):375-386. PubMed ID: 30265161
[No Abstract] [Full Text] [Related]
15. CD40-activated B cells contribute to mesothelioma tumor regression.
Jackaman C; Cornwall S; Graham PT; Nelson DJ
Immunol Cell Biol; 2011 Feb; 89(2):255-67. PubMed ID: 20628372
[TBL] [Abstract][Full Text] [Related]
16. T-cell activation induced by anti-CD3 x anti-B-cell lymphoma monoclonal antibody is enhanced by pretreatment of lymphoma cells with soluble CD40 ligand.
Wooldridge JE; Dahle CE; Weiner GJ
Cancer Immunol Immunother; 1997; 45(3-4):174-9. PubMed ID: 9435867
[TBL] [Abstract][Full Text] [Related]
17. Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas.
Funakoshi S; Longo DL; Murphy WJ
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):93-101. PubMed ID: 8732692
[TBL] [Abstract][Full Text] [Related]
18. CD40-mediated immune cell activation enhances response to anti-PD-1 in murine intrahepatic cholangiocarcinoma.
Diggs LP; Ruf B; Ma C; Heinrich B; Cui L; Zhang Q; McVey JC; Wabitsch S; Heinrich S; Rosato U; Lai W; Subramanyam V; Longerich T; Loosen SH; Luedde T; Neumann UP; Desar S; Kleiner D; Gores G; Wang XW; Greten TF
J Hepatol; 2021 May; 74(5):1145-1154. PubMed ID: 33276030
[TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses.
Murphy WJ; Welniak L; Back T; Hixon J; Subleski J; Seki N; Wigginton JM; Wilson SE; Blazar BR; Malyguine AM; Sayers TJ; Wiltrout RH
J Immunol; 2003 Mar; 170(5):2727-33. PubMed ID: 12594303
[TBL] [Abstract][Full Text] [Related]
20. Induction of dendritic cell costimulator molecule expression is suppressed by T cells in the absence of antigen-specific signalling: role of cluster formation, CD40 and HLA-class II for dendritic cell activation.
McLellan AD; Heiser A; Hart DN
Immunology; 1999 Oct; 98(2):171-80. PubMed ID: 10540215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
